89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

Rhea-AI Summary

89bio, a clinical-stage biopharmaceutical company focusing on therapies for liver and cardio-metabolic diseases, will participate in the H.C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022, at 11:30 AM ET.

Management will engage in a fireside chat and one-on-one investor meetings. The presentation will be available via webcast, accessible here.

SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 6^th Annual NASH Investor Conference on Monday, October 17, 2022 at 11:30 AM ET.

The webcast of the presentation will be accessible here and in the investor section of 89bio’s website.

About 89bio 
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact: 
Ryan Martins 
Chief Financial Officer 
investors@89bio.com

Media Contact: 
Lauren Barbiero
Real Chemistry
lbarbiero@realchemistry.com

 

FAQ

What is 89bio's focus in the biopharmaceutical industry?

89bio is dedicated to developing therapies for liver and cardio-metabolic diseases.

When is 89bio presenting at the H.C. Wainwright NASH Investor Conference?

89bio will present on October 17, 2022, at 11:30 AM ET.

Where can I watch the 89bio presentation from the NASH Investor Conference?

The presentation will be available via webcast, accessible through the company's website.

What is 89bio's lead candidate for clinical development?

89bio's lead candidate is pegozafermin, targeting non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

What is the significance of pegozafermin in 89bio's pipeline?

Pegozafermin is a potentially best-in-class FGF21 analog designed to improve treatment options for patients.